The Fracture Incidence and Safety of Teriparatide and Bisphosphonate in Postmenopausal Women With Osteoporosis: A Meta-Analysis.

特立帕肽 医学 骨质疏松症 双膦酸盐 不利影响 入射(几何) 荟萃分析 内科学 随机对照试验 骨矿物 物理 光学
作者
Qi Zhong,Yuanyue Liao,Wen Zou
出处
期刊:PubMed
链接
标识
摘要

To evaluate the anti-fracture effect and adverse effects of teriparatide versus bisphosphonate on postmenopausal osteoporosis. This study will provide evidence-based practice for the clinical selection of more effective and safer drugs for these patients.We searched PubMed, Embase, and the Cochrane Library from database inception to July 2022. The keywords included "fracture"; "teriparatide", "bisphosphonate", "postmenopausal women", and "osteoporosis". Randomized controlled trials (RCTs) comparing teriparatide versus bisphosphonates on the risk of fracture and adverse effects in postmenopausal osteoporosis were included in the analysis.Finally, 3376 participants were recruited in all 5 RCTs. The results revealed that teriparatide could decrease the rate of clinical vertebral fracture (OR=1.97, 95% CI=1.43-2.73, I2 = 0%, P < .0001) and new vertebral fractures (OR=2.44, 95% CI=1.70-3.50, I2 = 0%, P < .00001) compared with bisphosphonate. AE results refer to the type and frequency of adverse effects related to drug treatment. The rate of treatment discontinuous due to AEs (OR=0.63, 95% CI=0.48-0.83, I2 = 44%, P = .0009) with teriparatide was significantly greater than that with bisphosphonate. However, there was no significant difference in the incidence of adverse events to death (OR=0.59, 95% CI=0.30-1.18, I2 = 0%, P = .13). The proportion of patients reporting adverse events in the teriparatide versus bisphosphonate groups was consistent across subgroups, except for the rate of dizziness (OR=0.53, 95% CI=0.31-0.90, I2 = 49%, P = .02).Among postmenopausal women with osteoporosis, clinical vertebral fractures and new vertebral fractures decreased more in patients receiving teriparatide than in those receiving bisphosphonate. Although there were no differences in adverse events across subgroups, patients receiving teriparatide had a higher rate of dizziness than those receiving bisphosphonate.The results of this work will provide a reference for clinicians to select appropriate anti-osteoporosis drugs by comprehensively considering individual differences such as fracture risk and dizziness tolerance.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852应助momo采纳,获得10
1秒前
此间少年发布了新的文献求助10
1秒前
王汉韬发布了新的文献求助10
1秒前
哈哈完成签到 ,获得积分10
2秒前
英俊的铭应助xn201120采纳,获得10
2秒前
闾丘惜萱完成签到,获得积分10
2秒前
baonali发布了新的文献求助10
4秒前
yyyhhh完成签到,获得积分10
6秒前
ZH完成签到 ,获得积分10
10秒前
10秒前
10秒前
ll完成签到,获得积分10
11秒前
纾缓完成签到,获得积分10
13秒前
潘善若发布了新的文献求助10
13秒前
18秒前
Willy完成签到,获得积分10
19秒前
20秒前
大模型应助史念薇采纳,获得10
20秒前
20秒前
科研通AI2S应助xn201120采纳,获得10
20秒前
22秒前
潘善若发布了新的文献求助10
22秒前
万能图书馆应助GooJohn采纳,获得10
23秒前
梨花酒完成签到,获得积分10
23秒前
阿里山完成签到,获得积分10
24秒前
momo发布了新的文献求助10
25秒前
Amai完成签到,获得积分10
27秒前
Panjiao完成签到 ,获得积分10
31秒前
31秒前
32秒前
33秒前
Owen应助xiaohu采纳,获得10
33秒前
潘善若发布了新的文献求助10
36秒前
Fengliguantou发布了新的文献求助10
37秒前
量子星尘发布了新的文献求助10
38秒前
李健的小迷弟应助momo采纳,获得10
39秒前
41秒前
大模型应助xueyu采纳,获得10
44秒前
做一只快乐的猪猪侠完成签到,获得积分20
44秒前
44秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136